Powder: -20°C for 3 years | In solvent: -80°C for 1 year
KM-023 is a new second-generation non-nucleoside reverse transcriptase inhibitor for the study of human immunodeficiency virus (HIV) type 1 infection.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 153.00 | |
5 mg | In stock | $ 380.00 | |
10 mg | In stock | $ 570.00 | |
25 mg | In stock | $ 916.00 | |
50 mg | In stock | $ 1,250.00 | |
100 mg | In stock | $ 1,680.00 | |
500 mg | In stock | $ 3,370.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 377.00 |
Description | KM-023 is a new second-generation non-nucleoside reverse transcriptase inhibitor for the study of human immunodeficiency virus (HIV) type 1 infection. |
In vivo | KM-023 demonstrated dose- and time-dependent nonlinear pharmacokinetic characteristics after single or multiple doses over a dose range (75-600 mg) in healthy subjects. KM-023 showed a 0.6-fold accumulation after multiple doses in the 600 mg dose group. The mean half-life values ranged between 20.7 and 31.2 hours. KM-023 was generally well tolerated without serious adverse events. KM-023 showed favorable tolerability in this study.[1] |
Molecular Weight | 325.36 |
Formula | C18H19N3O3 |
CAS No. | 1097628-00-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 11 mg/mL (33.81 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
KM-023 1097628-00-6 Microbiology/Virology Proteases/Proteasome HIV Protease inhibitor inhibit